Xencor, Inc. (NASDAQ: XNCR) is a Healthcare company (Biotechnology) with a market capitalization of $2.6B. The Maz Rating grades it against the other companies in its sector.
Xencor, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $34.50, Xencor, Inc. trades at 13.0x sales and 4.7x book value. Over the last twelve months it generated about $200M of revenue and a net loss of $117M. It runs a gross margin of 97.4%, an operating margin of -72.7% and a net margin of -58.8%. It shows return on equity of -21.3%, return on invested capital of -20.2% and a free cash flow yield of -6.8%. On the balance sheet: a debt-to-equity ratio of 0.29 and a current ratio of 6.54. Over the past 52 weeks the share price ranged from $10.38 to $40.60, with a beta of 0.90.
Xencor, Inc. does not currently pay a dividend.
28 Wall Street analyst ratings cover the stock: 1 Strong Buy, 24 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Xencor, Inc. (XNCR) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.54% / 30% · (Cash+Inv) / Mkt Cap (36m) 27.8% / 30% · Interest income / Revenue 4.20% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 4.54% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 19.4% / 33% · Receivables / Mkt Cap (36m) 3.10% / 49% · Interest income / Revenue 4.20% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 4.54% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 19.4% / 33.33% · Receivables / Mkt Cap (24m) 3.10% / 33.33% · Interest income / Revenue 4.20% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 10.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 59.7% / 33.33% · Receivables / Avg Assets (4Q) 4.77% / 33.33% · Interest income / Revenue 4.20% / 5% | Fail |
| FTSE | Debt / Total Assets 12.3% / 33.33% · (Cash+ST Inv) / Total Assets 52.6% / 33.33% · (Cash+Recv) / Total Assets 61.0% / 33.33% · Interest income / Revenue 4.20% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Xencor, Inc. (XNCR) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Xencor, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 4.20% of each dividend: Xencor, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.